SPY759.06+0.26%QQQ690.90+0.40%BTC/USD68,438.77−4.11%DIA523.26+0.15%GLD355.86+0.27%TLT79.57−0.19%

CRISPR Therapeutics AG

CRSPNASDAQ

Trade with Public

$42.62

-3.13-6.84%

Last update: Nov 12, 7:35 PM

Overview News Charts Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

CRISPR Therapeutics (CRSP) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for CRISPR Therapeutics (CRSP) stock.

Analyst Consensus — 24 Analysts

2S.Buy

11Buy

10Hold

1Sell

# Analysts24

Latest Upgrades and Downgrades for CRISPR Therapeutics Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
—	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$88→$90
—	Wells Fargo	Yanan Zhu	PT Cut	Equal-Weight	$75→$70
—	Needham	Gil Blum	Maintained	Buy	$82
—	UBS	Joon Lee	Initiate	Neutral	$52
—	Citizens	Silvan Turkcan	Maintained	Market Outperform	$80
—	Needham	Gil Blum	Maintained	Buy	$82
—	Citizens	Silvan Turkcan	Maintained	Market Outperform	$80
—	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$82→$88
—	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$80
—	Citizens	Silvan Turkcan	Maintained	Market Outperform	$80
—	Bernstein	William Pickering	PT Raise	Market Perform	$50→$56
—	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$80→$82
—	Piper Sandler	Edward Tenthoff	PT Raise	Overweight	$105→$110
—	Chardan Capital	Geulah Livshits	PT Raise	Buy	$74→$76
—	TD Cowen	Tyler Van Buren	PT Raise	Hold	$40→$45
—	Evercore ISI Group	Liisa Bayko	PT Raise	Outperform	$62→$74
—	Needham	Gil Blum	PT Raise	Buy	$80→$82
—	Citizens	Silvan Turkcan	PT Cut	Market Outperform	$86→$80
—	Needham	Gil Blum	Maintained	Buy	$80
—	Citizens	Silvan Tuerkcan	Maintained	Market Outperform	$86

CRISPR Therapeutics AG

CRISPR Therapeutics (CRSP) Stock Price Target 2026

Latest Upgrades and Downgrades for CRISPR Therapeutics Stock

CRISPR Therapeutics (CRSP) Stock Price Target 2026

Latest Upgrades and Downgrades for CRISPR Therapeutics Stock

Analyst Ratings News

CRISPR Therapeutics Highlights Substantial Lipid Reductions with Investigational Gene Editing Therapy

PRO
Citigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $90

PRO
Wells Fargo Maintains Equal-Weight on CRISPR Therapeutics, Lowers Price Target to $70

PRO
Needham Reiterates Buy on CRISPR Therapeutics, Maintains $82 Price Target

PRO
UBS Initiates Coverage On CRISPR Therapeutics with Neutral Rating, Announces Price Target of $52

PRO
Citizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target

People Also Watch

People Also Watch

Analyst Ratings News

CRISPR Therapeutics Highlights Substantial Lipid Reductions with Investigational Gene Editing Therapy

PRO
Citigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $90

PRO
Wells Fargo Maintains Equal-Weight on CRISPR Therapeutics, Lowers Price Target to $70

PRO
Needham Reiterates Buy on CRISPR Therapeutics, Maintains $82 Price Target

PRO
UBS Initiates Coverage On CRISPR Therapeutics with Neutral Rating, Announces Price Target of $52

PRO
Citizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target

CRISPR Therapeutics AG

CRISPR Therapeutics (CRSP) Stock Price Target 2026

Latest Upgrades and Downgrades for CRISPR Therapeutics Stock

CRISPR Therapeutics (CRSP) Stock Price Target 2026

Latest Upgrades and Downgrades for CRISPR Therapeutics Stock

Analyst Ratings News

CRISPR Therapeutics Highlights Substantial Lipid Reductions with Investigational Gene Editing Therapy

PROCitigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $90

PROWells Fargo Maintains Equal-Weight on CRISPR Therapeutics, Lowers Price Target to $70

PRONeedham Reiterates Buy on CRISPR Therapeutics, Maintains $82 Price Target

PROUBS Initiates Coverage On CRISPR Therapeutics with Neutral Rating, Announces Price Target of $52

PROCitizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target

People Also Watch

People Also Watch

Analyst Ratings News

CRISPR Therapeutics Highlights Substantial Lipid Reductions with Investigational Gene Editing Therapy

PROCitigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $90

PROWells Fargo Maintains Equal-Weight on CRISPR Therapeutics, Lowers Price Target to $70

PRONeedham Reiterates Buy on CRISPR Therapeutics, Maintains $82 Price Target

PROUBS Initiates Coverage On CRISPR Therapeutics with Neutral Rating, Announces Price Target of $52

PROCitizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target

PRO
Citigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $90

PRO
Wells Fargo Maintains Equal-Weight on CRISPR Therapeutics, Lowers Price Target to $70

PRO
Needham Reiterates Buy on CRISPR Therapeutics, Maintains $82 Price Target

PRO
UBS Initiates Coverage On CRISPR Therapeutics with Neutral Rating, Announces Price Target of $52

PRO
Citizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target

PRO
Citigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $90

PRO
Wells Fargo Maintains Equal-Weight on CRISPR Therapeutics, Lowers Price Target to $70

PRO
Needham Reiterates Buy on CRISPR Therapeutics, Maintains $82 Price Target

PRO
UBS Initiates Coverage On CRISPR Therapeutics with Neutral Rating, Announces Price Target of $52

PRO
Citizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target